Based on these findings, monotherapy with KRAS inhibitors, or combination therapy with KRAS inhibitors plus cancer immunotherapies such as ICIs, is expected to be highly effective in BTC patients harboring KRAS mutations. The gene discussed is KRAS; the disease is cancer.